Publications scientifiques en oncologie

TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer
2021
Author  Demeule M, Charfi C, Currie JC, Laroque A, Zgheib A, Kozelko S, Béliveau R, Marsolais C, Annabi B 
Demeule M, Charfi C, Currie J-C, et al. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer. Cancer Sci. 2021;00:1–18.
TH1901, a novel curcumin-peptide conjugate for the treatment of Sortilin-positive (SORT1+) cancer [abstract].
2020
Cancer Res.
Annabi B, Demeule M, Currie J-C, et al.
80(16 suppl):6362. Proceedings of the Annual Meeting of the American Association for Cancer Research 2020.
TH1901, a novel curcumin-peptide conjugate for the treatment of Sortilin-positive (SORT1+) cancer.
2020
Annabi B, Demeule M, Currie J-C, et al.
Poster #4386 presented at: Annual Meeting of the American Association for Cancer Research; June 22-24, 2020; virtual.
Increasing potency of anticancer drugs through Sortilin receptor-mediated cancer therapy: A new targeted approach for the treatment of ovarian cancer [abstract].
2020
Cancer Res.
Marsolais C, Demeule M, Currie J-C, et al.
80(16 suppl):1061. Proceedings of the Annual Meeting of the American Association for Cancer Research 2020.
Increasing potency of anticancer drugs through Sortilin receptor-mediated cancer therapy: A new targeted approach for the treatment of ovarian cancer.
2020
Marsolais C, Demeule M, Currie J-C, et al.
Oral presentation at: Annual Meeting of the American Association for Cancer Research; June 22-24, 2020; virtual. Session VMS.ET04.01.